TAIMED BIOLOGICS Business Summary

TaiMed Biologics Inc. (4147.TWO) operates a hybrid biopharmaceutical business model that integrates the development of proprietary monoclonal antibodies (mAbs) with high-margin contract development and manufacturing organization (CDMO) services. Revenue is primarily generated through product sales and licensing royalties from its flagship HIV-1 treatment, Trogarzo (ibalizumab), alongside milestone payments from global partners such as Theratechnologies and AcedrA BioPharmaceuticals. The company’s primary business segments include Biologic Drug Development, focused on next-generation long-acting therapies like the TMB-365/380 combination, and Manufacturing Services, which leverages its FDA-inspected Zhubei facility to provide cGMP protein production for external clients. In the competitive landscape, TaiMed contends with global leaders such as Gilead Sciences, ViiV Healthcare, Merck & Co., and CytoDyn; however, it maintains a distinct market position as a specialized provider of long-acting biologics for heavily treatment-experienced (HTE) patients with multi-drug resistance. The leadership team is spearheaded by Chairman and CEO Dr. Jimmy (Chin-Ming) Chang, a pharmaceutical veteran with over 25 years of experience at Eli Lilly and Allergan who has transitioned the firm from a single-asset specialist to a diversified biologics innovator. The company’s scientific pedigree is anchored by founder and Chief Scientific Board member Dr. David Ho, the world-renowned HIV researcher credited with the "cocktail therapy" breakthrough. Strategic oversight is supported by a board featuring representatives from the Ruentex Group, including Board Chairman Ming-Tsuen Chen. TaiMed is backed by a robust investor base that includes the Taiwan National Development Fund and the Ruentex Group, providing the institutional stability and capital necessary to advance its antibody-drug conjugate (ADC) platform and expand into autoimmune disease indications.